Veracyte outlined plans to launch TrueMRD, a sequencing‑based minimal residual disease assay, in the first half of the year with an initial indication for muscle‑invasive bladder cancer (MIBC). CEO Mark Stapley said the company expects reimbursement and is pursuing separate billing codes for initial testing and longitudinal surveillance, while Prosigna prognostic breast cancer sequencing is planned as an LDT this summer. Veracyte framed TrueMRD as differentiated by whole‑transcriptome sequencing and a development pathway tied to clinical utility readouts. For diagnostic stakeholders: sequencing‑based MRD assays aim to integrate broader transcriptomic signals to inform recurrence risk and treatment response, a strategy that may affect payor coverage discussions and clinical guideline inclusion.